Seven recommendations developed, including use of floating immunoreactive trypsinogen cutoff over fixed cutoff.

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

The most common projected cancers in adults were lung cancer, colon cancer, leukemia, bladder cancer, and stomach cancer.

The updated recommendations are pending final approval by the director of the CDC and the Department of Health and Human Services.

The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. It was approved in April 2022 for the treatment of adults with symptomatic New York Heart Association (NYHA) class ...

Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, significantly reduced hemoglobin A1c (HbA1c) in adults with type 2 diabetes (T2D) and inadequate glycemic control with diet ...

Treatment options are limited for those with sudden liver failure and the condition has a death rate as high as 50%.

When used with the companion app, the smart belt automatically alerts caregivers when a fall or impact is detected.

In this younger patient population, diazepam nasal spray was readily absorbed and demonstrated a consistent PK profile with that of older children and adults aged 6 to 59 years.